Neurocrine to Buy Soleno for $2.9 Billion, Picks Up Prader‑Willi Drug VYKAT XR

Neurocrine Biosciences agreed to acquire Soleno Therapeutics in an all‑cash deal valued at about $2.9 billion, a move that brings VYKAT XR, the first FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome, into Neurocrine’s commercial stable.

The transaction, announced April 6, will pay Soleno shareholders $53 per share — roughly a 34% premium to Soleno’s April 2 closing price and about 51% to its 30‑day volume‑weighted average price. The companies signed a merger agreement on April 5.

Deal structure and timing

The agreement is structured as a cash tender offer followed by a merger under Section 251(h) of Delaware law. A Neurocrine subsidiary will launch the tender offer within 10 business days of signing and keep it open for at least 20 business days, subject to extensions. If a majority of Soleno shares are validly tendered and not withdrawn, the subsidiary will accept the shares and Neurocrine will complete a back‑end merger to take full ownership.

Both boards have approved the deal and Soleno’s board is recommending that shareholders tender. Neurocrine said it will fund the acquisition with cash on hand and "a modest amount of pre‑payable debt," and emphasized that the closing is not conditioned on financing. The parties expect the transaction to close in about 90 days, subject to regulatory approvals and customary closing conditions.

Why Neurocrine is paying up

VYKAT XR (diazoxide choline extended‑release tablets) was approved by the Food and Drug Administration on March 26, 2025, for treatment of hyperphagia in adults and children age 4 and older with Prader‑Willi syndrome (PWS). PWS is a genetic disorder that affects an estimated 10,000 people in the United States and is marked by developmental delays, hormone deficiencies and a pathological, insatiable hunger that can lead to severe obesity and life‑threatening complications.

For a newly launched orphan drug, VYKAT XR posted strong early sales: Soleno reported $190.4 million in product revenue for its first full year on the market, including $91.7 million in fourth‑quarter 2025 sales. As of Dec. 31, Soleno said it had received 1,250 patient start forms, 859 active patients on therapy and prescriptions from 630 unique prescribers. The company also reported payer contracts covering "over 185 million lives."

Those launch metrics — unusually robust for a narrowly targeted orphan therapy — help explain Neurocrine’s willingness to pay a significant premium for a ready‑to‑scale product with established commercial traction.

Quotes from the companies

Neurocrine CEO Kyle W. Gano, Ph.D., framed the acquisition as a strategic step to broaden the company’s commercial footprint beyond its existing neurological and endocrine products.

"This transaction will advance Neurocrine’s mission to deliver life‑changing treatments while accelerating our revenue growth and portfolio diversification strategy," Gano said in a joint statement. "We look forward to working together to continue to help patients in need."

Soleno CEO Anish Bhatnagar, M.D., described Neurocrine as a better‑resourced steward for VYKAT XR and its patient community.

"Neurocrine is the right strategic partner to expand the reach of VYKAT XR in the Prader‑Willi syndrome community given their experience in endocrinology and rare disease," Bhatnagar said.

Financial position, protections and filings

Soleno entered the deal in a relatively strong position: it reported net income of $20.9 million for 2025 and finished the year with $506.1 million in cash and marketable securities, reducing its immediate need for new financing and potentially increasing its leverage in negotiations.

The merger agreement includes reverse termination and break fees to protect both sides if the transaction is derailed. If U.S. antitrust authorities block the deal or impose unacceptable conditions, Neurocrine would owe Soleno a reverse termination fee of $141.5 million. If Soleno terminates to accept a superior proposal under specified circumstances, it would owe Neurocrine a $95.25 million break fee.

The deal is subject to the expiration or termination of the Hart‑Scott‑Rodino waiting period; both companies must file the necessary HSR forms within 15 business days of signing. Neurocrine will detail the tender offer terms in a Schedule TO filing with the Securities and Exchange Commission, and Soleno will respond with a Schedule 14D‑9 containing the board’s recommendation and the factors it considered.

Patient access and payer questions

The acquisition raises practical questions for patients and caregivers in the PWS community about access, coverage and support under new ownership. Soleno’s launch figures point to broad coverage by lives, but they do not reveal how frequently patients encounter denials, prior‑authorization hurdles or high out‑of‑pocket costs. The companies have not disclosed VYKAT XR’s list price in SEC filings.

Neurocrine has emphasized its commercial infrastructure and experience in rare endocrine disorders as assets that could expand real‑world access. How payers respond under new ownership and how aggressively Neurocrine invests in patient services and reimbursement support will determine whether the drug’s reach widens.

Broader industry context

The acquisition fits a wider pattern in biopharma: larger companies paying premiums for orphan drugs that have cleared regulatory and early commercial risks rather than investing in higher‑risk, earlier‑stage programs. For Neurocrine, the deal adds a third marketed product alongside INGREZZA (valbenazine), which generated $2.51 billion in 2025 revenue, and CRENESSITY (crinecerfont), which brought in $301 million that year.

Neurocrine said VYKAT XR is supported by an intellectual‑property estate expected to extend into the mid‑2040s, giving the product a potential long runway if it maintains market position.

What comes next

Shareholders will see the formal offer and related materials in filings on the SEC’s EDGAR system and on the companies’ investor‑relations websites. The tender offer will remain open for at least 20 business days, and closing depends on regulatory clearances and customary conditions.

For patients, clinicians and payers, the immediate questions are practical: will Neurocrine’s resources improve access and affordability for people living with Prader‑Willi syndrome, and how quickly will the company move to scale support services under new ownership?

The acquisition represents a calculated bet by Neurocrine that a first‑in‑class therapy for a small, clearly defined patient population can deliver durable commercial growth and that integrating Soleno’s young franchise will be more efficient than building a comparable product from the ground up.